Association of aberrant DNA methylation in Apcmin/+ mice with the epithelial-mesenchymal transition and Wnt/β-catenin pathways: Genome-wide analysis using MeDIP-seq

Cell and Bioscience

Volumn 5, Issue 1, 2015, Pages

  Guo, Yue ^a   Lee, J Hun ^c   Shu, Limin ^a   Huang, Ying ^a   Li, Wenji ^a   Zhang, Chengyue ^a   Yang, Anne Yuqing ^a   Boyanapalli, Sarandeep S S ^a   Perekatt, Ansu ^b   Hart, Ronald P ^b   Verzi, Michael ^b   Kong, A N Tony ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c CHA University   (South Korea)

Author keywords

DNA methylation; Epigenetic; Epithelial mesenchymal transition pathway; MeDIP seq; Wnt catenin pathway

Indexed keywords

MUS;

EID: 85027926963     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/s13578-015-0013-2     Document Type: Article

References (65)

1. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010;19(5):698-711. doi:10.1016/j.devcel.2010.10.005.
2. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27. doi:10.1016/j.cell.2012.06.013.
3. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science. 2001;293(5532):1068-70. doi: 10.1126/science.1063852.
4. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-92. doi: 10.1016/j.cell.2007.01.029.
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042-54. doi:10.1056/NEJMra023075.
6. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525-32. doi:10.1056/NEJM198809013190901.
7. Guo Y, Su Z-Y, Kong A-NT. Current perspectives on epigenetic modifications by dietary chemopreventive and herbal phytochemicals. Curr Pharmacol Rep. 2015;1-13. doi:10.1007/s40495-015-0023-0.
8. Harrison S, Benziger H. The molecular biology of colorectal carcinoma and its implications: a review. Surgeon. 2011;9(4):200-10. doi:10.1016/j.surge.2011.01.011.
9. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87(2):159-70.
10. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275(5307):1787-90.
11. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422-6. doi:10.1038/18884.
12. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int. 2012;2012:509348. doi:10.1155/2012/509348.
13. Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, et al. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review. Int J Cancer J Int du Cancer. 2011;128(5):1080-94. doi:10.1002/ijc.25432.
14. Belshaw NJ, Pal N, Tapp HS, Dainty JR, Lewis MP, Williams MR, et al. Patterns of DNA methylation in individual colonic crypts reveal aging and cancer-related field defects in the morphologically normal mucosa. Carcinogenesis. 2010;31(6):1158-63. doi:10.1093/carcin/bgq077.
15. Ying J, Poon FF, Yu J, Geng H, Wong AH, Qiu GH, et al. DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer. 2009;100(4):663-9. doi:10.1038/sj.bjc.6604888.
16. Guo Y, Shu L, Zhang C, Su ZY, Kong AN. Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1. Biochem Pharmacol. 2015;94(2):69-78. doi:10.1016/j.bcp.2015.01.009.
17. Hibi K, Mizukami H, Shirahata A, Goto T, Sakata M, Saito M, et al. Aberrant methylation of the UNC5C gene is frequently detected in advanced colorectal cancer. Anticancer Res. 2009;29(1):271-3.
18. Li X, Lu P, Li B, Zhang W, Luo K. Effects of iodine-125 seeds on the methylation of SFRP and P16 in colorectal cancer. Exp Ther Med. 2013;6(5):1225-8. doi:10.3892/etm.2013.1298.
19. Halberg RB, Katzung DS, Hoff PD, Moser AR, Cole CE, Lubet RA, et al. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. P Natl Acad Sci USA. 2000;97(7):3461-6. doi:10.1073/pnas.050585597.
20. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-67.
21. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265-73. doi:10.1038/nrc2620.
22. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286-98. doi:10.1038/nrg2005.
23. Down TA, Rakyan VK, Turner DJ, Flicek P, Li H, Kulesha E, et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat Biotechnol. 2008;26(7):779-85. doi:10.1038/nbt1414.
24. Alisch RS, Wang T, Chopra P, Visootsak J, Conneely KN, Warren ST. Genome-wide analysis validates aberrant methylation in fragile X syndrome is specific to the FMR1 locus. BMC Med Genet. 2013;14:18. doi:10.1186/1471-2350-14-18.
25. Fang WJ, Zheng Y, Wu LM, Ke QH, Shen H, Yuan Y, et al. Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients. Asian Pac J Cancer Prev: APJCP. 2012;13(5):1917-21.
26. Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G. Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics. 2010;11:137. doi:10.1186/1471-2164-11-137.
27. Grimm C, Chavez L, Vilardell M, Farrall AL, Tierling S, Bohm JW, et al. DNA-methylome analysis of mouse intestinal adenoma identifies a tumour-specific signature that is partly conserved in human colon cancer. PLoS Genet. 2013;9(2):e1003250. doi:10.1371/journal.pgen.1003250.
28. Tan LJ, Zhu H, He H, Wu KH, Li J, Chen XD, et al. Replication of 6 obesity genes in a meta-analysis of genome-wide association studies from diverse ancestries. PLoS One. 2014;9(5):e96149. doi:10.1371/journal.pone.0096149.
29. Huhn S, Ingelfinger D, Bermejo JL, Bevier M, Pardini B, Naccarati A, et al. Polymorphisms in CTNNBL1 in relation to colorectal cancer with evolutionary implications. Int J Mol Epidemiol Genet. 2011;2(1):36-50.
30. Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, et al. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol. 2006;210(2):147-54. doi:10.1002/path.2030.
31. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2 Suppl 1:S4-11. doi:10.1038/ncponc0354.
32. De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell. 2012;21(5):655-67. doi:10.1016/j.ccr.2012.03.045.
33. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers (Basel). 2013;5(2):676-713. doi:10.3390/cancers5020676.
34. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6-21. doi:10.1101/gad.947102.
35. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-8. doi:10.1172/JCI39104.
36. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118(3):277-9. doi:10.1016/j.cell.2004.07.011.
37. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442-54. doi:10.1038/nrc822.
38. Chen X, Halberg RB, Burch RP, Dove WF. Intestinal adenomagenesis involves core molecular signatures of the epithelial-mesenchymal transition. J Mol Histol. 2008;39(3):283-94. doi:10.1007/s10735-008-9164-3.
39. Lee K, Nelson CM. New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. Int Rev Cell Mol Biol. 2012;294:171-221. doi:10.1016/B978-0-12-394305-7.00004-5.
40. Kiesslich T, Pichler M, Neureiter D. Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol. 2013;1(1):3-11. doi:10.3892/mco.2012.28.
41. Cieslik M, Hoang SA, Baranova N, Chodaparambil S, Kumar M, Allison DF, et al. Epigenetic coordination of signaling pathways during the epithelial-mesenchymal transition. Epigenetics Chromatin. 2013;6(1):28. doi:10.1186/1756-8935-6-28.
42. Sodir NM, Chen X, Park R, Nickel AE, Conti PS, Moats R, et al. Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res. 2006;66(17):8430-8. doi:10.1158/0008-5472.CAN-06-1437.
43. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007;67(19):9066-76. doi:10.1158/0008-5472.CAN-07-0575.
44. Scartozzi M, Bearzi I, Mandolesi A, Giampieri R, Faloppi L, Galizia E, et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer. 2011;104(11):1786-90. doi:10.1038/bjc.2011.161.
45. Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, et al. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene. 2011;30(47):4707-20. doi:10.1038/onc.2011.181.
46. Yu H, Jin GZ, Liu K, Dong H, Yu H, Duan JC, et al. Twist2 is a valuable prognostic biomarker for colorectal cancer. World J Gastroenterol: WJG. 2013;19(15):2404-11. doi:10.3748/wjg.v19.i15.2404.
47. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(17):3877-85. doi:10.1200/JCO.2005.02.196.
48. Thathia SH, Ferguson S, Gautrey HE, van Otterdijk SD, Hili M, Rand V, et al. Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica. 2012;97(3):371-8. doi:10.3324/haematol.2011.049593.
49. Dhir M, Montgomery EA, Glockner SC, Schuebel KE, Hooker CM, Herman JG, et al. Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointestinal Surg Off J Soc Surg Alimentary Tract. 2008;12(10):1745-53. doi:10.1007/s11605-008-0633-5.
50. Wang LS, Kuo CT, Huang TH, Yearsley M, Oshima K, Stoner GD, et al. Black raspberries protectively regulate methylation of Wnt pathway genes in precancerous colon tissue. Cancer Prev Res. 2013;6(12):1317-27. doi:10.1158/1940-6207.CAPR-13-0077.
51. Wang LS, Kuo CT, Stoner K, Yearsley M, Oshima K, Yu J, et al. Dietary black raspberries modulate DNA methylation in dextran sodium sulfate (DSS)-induced ulcerative colitis. Carcinogenesis. 2013;34(12):2842-50. doi:10.1093/carcin/bgt310.
52. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009;457(7229):608-11. doi:10.1038/nature07602.
53. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469-80. doi:10.1016/j.cell.2006.10.018.
54. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27-36. doi:10.1093/carcin/bgp220.
55. Miao CG, Yang YY, He X, Xu T, Huang C, Huang Y, et al. New advances of microRNAs in the pathogenesis of rheumatoid arthritis, with a focus on the crosstalk between DNA methylation and the microRNA machinery. Cell Signal. 2013;25(5):1118-25. doi:10.1016/j.cellsig.2013.01.024.
56. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10(5):295-304. doi:10.1038/nrg2540.
57. Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J. 2009;50(4):455-63. doi:10.3349/ymj.2009.50.4.455.
58. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104(40):15805-10. doi: 10.1073/pnas.0707628104.
59. Tahara T, Yamamoto E, Madireddi P, Suzuki H, Maruyama R, Chung W, et al. Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. Gastroenterology. 2014;146(2):530-38 e5. doi:10.1053/j.gastro.2013.10.060.
60. Zhang GJ, Xiao HX, Tian HP, Liu ZL, Xia SS, Zhou T. Upregulation of microRNA-155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin-1 expression. Int J Mol Med. 2013;31(6):1375-80. doi:10.3892/ijmm.2013.1348.
61. Sims 3rd RJ, Millhouse S, Chen CF, Lewis BA, Erdjument-Bromage H, Tempst P, et al. Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol Cell. 2007;28(4):665-76. doi:10.1016/j.molcel.2007.11.010.
62. Khor TO, Cheung WK, Prawan A, Reddy BS, Kong AN. Chemoprevention of familial adenomatous polyposis in Apc(Min/+) mice by phenethyl isothiocyanate (PEITC). Mol Carcinog. 2008;47(5):321-5. doi:10.1002/mc.20390.
63. Yang AY, Lee JH, Shu L, Zhang C, Su ZY, Lu Y, et al. Genome-wide analysis of DNA methylation in UVB- and DMBA/TPA-induced mouse skin cancer models. Life Sci. 2014;113(1-2):45-54. doi:10.1016/j.lfs.2014.07.031.
64. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with tophat and cufflinks. Nat Protoc. 2012;7(3):562-78. doi:10.1038/nprot.2012.016.
65. Zhu LJ, Gazin C, Lawson ND, Pages H, Lin SM, Lapointe DS, et al. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinf. 2010;11:237. doi:10.1186/1471-2105-11-237.